The Trader Harbor
  • Business
  • Politics
  • World News
  • Stocks
  • Business
  • Politics
  • World News
  • Stocks

The Trader Harbor

Politics

Senate confirms Dr Marty Makary as Trump’s FDA chief

by admin March 26, 2025
March 26, 2025
Senate confirms Dr Marty Makary as Trump’s FDA chief

President Donald Trump’s choice to lead the Food and Drug Administration (FDA), Johns Hopkins School of Medicine professor Dr. Marty Makary, was confirmed in the Senate on Tuesday.

His confirmation was cemented just hours after he cleared one last procedural test vote earlier in the evening. 

The Senate voted 56-44 to invoke cloture on the nomination prior to his final confirmation.

Makary, a former Fox News medical contributor, went before the Senate Committee on Health, Education, Labor and Pensions (HELP) earlier this month and answered various questions on vaccines, chronic illness, food safety and abortion. 

During his hearing, the nominee faced scrutiny over an FDA vaccine meeting that was reportedly postponed at the last minute. 

‘So if you are confirmed, will you commit to immediately reschedule that FDA Vaccine Advisory Committee meeting to get the expert views?’ Sen. Patty Murray, D-Wash., asked Makary at the time. 

He responded that he ‘would reevaluate which topics deserve a convening of the advisory committee members on [Vaccines and Related Biological Products Advisory Committee] and which may not require a convening.’ 

When this response wasn’t good enough for Murray, Makary flipped the question, telling her to confront the Biden administration. ‘Well, you can ask the Biden administration that chose not to convene the committee meeting for the COVID vaccine booster,’ he said. 

He was referring to the Biden administration in 2021 pushing through FDA approval for a COVID-19 booster for everyone over the age of 18. 

‘The FDA did not hold a meeting of the Vaccines and Related Biological Products Advisory Committee on these actions,’ read a press release at the time, ‘as the agency previously convened the committee for extensive discussions regarding the use of booster doses of COVID-19 vaccines and, after review of both Pfizer’s and Moderna’s EUA requests, the FDA concluded that the requests do not raise questions that would benefit from additional discussion by committee members.’

Committee member Dr. Paul Offit, director of the Vaccine Education Center at Children’s Hospital of Philadelphia, criticized the administration’s move, saying, ‘We’re being asked to approve this as a three-dose vaccine for people 16 years of age and older, without any clear evidence if the third dose for a younger person when compared to an elderly person is of value.’

Makary has long been a critic of the administration he will now lead. He wrote an opinion piece in 2021, calling for ‘fresh leadership at the FDA to change the culture at the agency and promote scientific advancement, not hinder it.’

‘We now have a generational opportunity in American healthcare,’ he said at his hearing. ‘President Trump and Secretary Kennedy’s focus on healthy foods has galvanized a grassroots movement in America. Childhood obesity is not a willpower problem, and the rise of early-onset Alzheimer’s is not a genetic cause. We should be, and we will, be addressing food as it impacts our health.’

This post appeared first on FOX NEWS

0
FacebookTwitterGoogle +Pinterest
previous post
GOP senator says Dr Oz ignored his questions on transgender issues, abortion
next post
Trump’s pick to lead NIH, Dr. Jay Bhattacharya, confirmed by Senate in party-line vote

Related Posts

Russia bombards Ukraine with drones hours after Trump...

May 19, 2025

Former Watergate prosecutor calls Trump gag order ‘so...

March 28, 2024

2024 Cash Dash: Harris nearly triples Trump’s fundraising...

September 6, 2024

Senate leaves Washington as government shutdown nears 3rd...

October 10, 2025

Johnson erupts over ‘dangerous’ Biden ‘cover-up’ as Democrats...

July 24, 2025

Protests spread across Iran as regime threatens US...

January 3, 2026

Waltz tells Iran to give up nuclear program...

March 24, 2025

First American hostage to be released from Gaza,...

January 31, 2025

MORNING GLORY: Trump meets Putin amid an era...

August 12, 2025

People in Gaza are thanking Trump for aid,...

June 12, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest

    • L.A. County sues Roblox, alleges platform makes it easy for adults to target children

      February 22, 2026
    • The Real Drivers of This Market: AI, Semis & Robotics

      February 22, 2026
    • S&P 500 Breaking Out Again: What This Means for Your Portfolio

      February 22, 2026
    • Trump torches ‘stupid’ AOC’s Munich showing, tees up fresh fight with progressive Democrats

      February 22, 2026
    • Why a credit freeze isn’t the end of identity theft

      February 22, 2026
    • DHS suspends TSA PreCheck, Global Entry as partial government shutdown continues

      February 22, 2026

    Categories

    • Business (1,459)
    • Politics (5,865)
    • Stocks (1,969)
    • Uncategorized (45)
    • World News (1,452)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: TheTraderHarbor, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 thetraderharbor.com | All Rights Reserved